INTRODUCTION {#s1}
============

Prostate cancer (PCa) is the most common malignancy diagnosed in men and the second leading cause of cancer-related death for men in the United States \[[@R1]\]. The American Cancer Society estimates that 161,360 new PCa cases and 26,730 PCa deaths will occur in 2017 \[[@R2]\]. Widespread use of prostate-specific antigen (PSA) screening could reduce mortality of PCa. However, PSA screening may contribute to overdiagnosis and overtreatment \[[@R3]\]. New predictive biomarkers are becoming an urgent need, such as single nucleotide polymorphism (SNP) \[[@R4]\]. Remarkably, Xu et al. found that SNPs of four genes in the inflammation pathway, including interleukin-10 (*IL-10*) could significantly predict the risk of PCa \[[@R5]\].

*IL-10* is a pleiotropic cytokine that modulates the function of several adaptive immunity-related cells \[[@R6]\]. *IL-10* is known to suppress the functions of both T lymphocytes and macrophages, working as a general dampener of the immune and inflammatory responses \[[@R7]\]. Huang et al. found that *IL-10* could suppress metastasis and growth of the tumor by inhibiting macrophage-derived angiogenic factors *in vivo* \[[@R8]\]. Richter et al. also found that *IL-10* transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration \[[@R9]\]. In addition, overexpression of *IL-10* was observed in PCa tissue by the analysis of type T1 and T2 cytokines in patients with PCa \[[@R10]\]. Yu et al. also found *IL-10* decreased stemness of human prostate cancer cells *in vitro* \[[@R11]\]. Based on these observations, *IL-10* may provide insights about screening and therapeutic intervention on neoplastic patients.

Kingo et al. identified that *IL-10* rs1800896 polymorphism may have an influence on *IL-10* mRNA expression and the expression of *IL-10 in vitro* \[[@R12]\]. Recently, a host of studies \[[@R5], [@R13]--[@R26]\] attached importance to evaluating whether *IL-10* rs1800896 polymorphism had effects on the risk of PCa. Some studies yielded relations between *IL-10* rs1800896 polymorphism and PCa risk \[[@R16], [@R19], [@R22]\], but other studies could not \[[@R5], [@R13]-[@R15], [@R17], [@R18], [@R20], [@R21], [@R23]-[@R26]\]. Small sample sizes, low statistical power, and clinical heterogeneity may contribute to these conflicting results. Therefore, we conducted this meta-analysis to review available evidence and evaluate the effects of rs1800896 polymorphism in *IL-10* gene on PCa susceptibility in the overall population.

RESULTS {#s2}
=======

Characteristics of the included studies {#s2_1}
---------------------------------------

We used the following searched terms like prostate cancer, prostatic neoplasm, prostate carcinoma, prostate neoplasms, polymorphism, polymorphisms, SNP, SNPs, rs1800896, Interleukin 10, *IL-10* and IL10 to identify relevant articles. Totally 195 articles were identified after an electronic and manual search (PubMed, 74 articles; EMBASE, 65 articles; CNKI, 5 articles; Google, 51 articles). Then 67 duplicates and 96 articles unrelated to this topic were removed. 32 articles remained for further full-text review. 17 articles were excluded due to the following reasons: eight articles investigated other diseases rather than PCa; three articles investigated other polymorphisms of *IL-10* gene; one article did not provide detailed genotyping data; three articles were reviews or meta-analyses; one article was excluded due to overlapping information with another study. One article was divided into two studies because it contains two different racial groups. Finally, 16 eligible studies in 15 articles with 6,301 patients and 6,510 controls were included in this meta-analysis. The selection for eligible studies was presented in Figure [1](#F1){ref-type="fig"}. Most of the included studies \[[@R5], [@R15], [@R16], [@R18]-[@R22], [@R24], [@R25]\] were population-based studies, focusing on Caucasians. In addition, we found that five studies \[[@R13]-[@R15], [@R21], [@R27]\] did not conform to Hardly-Weinberg equilibrium (HWE). The phenomenon may be partly attributed to genotyping error, population stratification and selection bias in the recruitment of controls. Moreover, the Newcastle-Ottawa Scale (NOS) scores of all included studies ranged from 5 to 7 stars, suggesting that these studies were of high methodological quality. The detailed characteristics of included studies are listed in Table [1](#T1){ref-type="table"}.

![Selection of eligible publications included in this meta-analysis](oncotarget-08-66204-g001){#F1}

###### Characteristics of included studies for the association between *IL-10* rs1800896 polymorphism and prostate cancer

  Author+year         Country   Ethnicity   SOC   Genotyping method   Case   Control   HWE   NOS                     
  ------------------- --------- ----------- ----- ------------------- ------ --------- ----- ----- ----- ----- ----- ---
  McCarron2002        UK        Caucasian   PB    PCR                 56     113       78    57    120   46    Yes   7
  Xu2005              Sweden    Caucasian   PB    MassARRAY           306    689       388   187   390   203   Yes   6
  Michaud2006         US        Mixed       PB    Taqman              290    599       356   383   857   523   Yes   7
  Faupel-Badger2008   US        Caucasian   PB    Taqman              85     251       173   73    194   115   Yes   6
  Omrani2008          Iran      Caucasian   HB    PCR                 5      31        5     2     98    3     No    5
  Zabaleta2008        US        Caucasian   HB    Taqman              126    239       110   86    206   102   Yes   6
  Zabaleta2008        US        African     HB    Taqman              7      38        21    13    74    42    No    6
  Kesarwani2009       India     Caucasian   PB    PCR                 12     78        69    45    103   111   No    6
  Wang2009            US        Caucasian   PB    Taqman              56     130       69    83    117   57    Yes   6
  Liu2010             China     Asian       PB    PCR                 4      36        222   3     27    240   Yes   7
  VanCleave2010       US        African     HB    Taqman              75     95        22    288   280   92    Yes   7
  Niu2011             China     Asian       HB    N/A                 18     56        24    20    26    42    No    6
  Dluzniewski2012     US        Caucasian   PB    MassARRAY           100    212       146   104   242   112   Yes   7
  Lanni2013           Italy     Caucasian   PB    Taqman              18     74        79    28    43    25    Yes   6
  Horvat2015          Croatia   Caucasian   HB    Taqman              24     59        37    24    54    42    Yes   6
  Winchester2017      US        Caucasian   PB    MassARRAY           136    305       179   140   254   134   No    7

SOC, source of controls; PB, population-based controls; HB, hospital-based controls; HWE, hardy-weinberg equilibrium; NOS, newcastle-ottawa scale.

Quantitative analysis {#s2_2}
---------------------

The findings of our meta-analysis uncovering the association between *IL-10* rs1800896 polymorphism and PCa was summarized in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. The meta-analysis revealed that individuals carrying GG genotypes had a 19% lower risk of developing PCa compared to those who carried AA genotypes in the overall population (GG vs. AA: OR, 0.81; 95% CI, 0.66--0.99, *P* = 0.044, Figure [2](#F2){ref-type="fig"}). Stratification analyses were conducted according to ethnicity, HWE, SOC and genotyping method. Ethnicity subgroup analysis indicated that the risk allele of rs1800896 in the *IL-10* gene was associated with the decreased risk of PCa among Caucasians in most of the comparisons (G vs. A: OR, 0.85; 95% CI, 0.76--0.96, *P* = 0.007, Figure [3](#F3){ref-type="fig"}), while the opposite result was found among Asians in the allele model (G vs. A: OR, 1.44; 95% CI, 1.06--1.97, *P* = 0.020, Figure [3](#F3){ref-type="fig"}) and dominant model. In addition, we failed to find this significant association among Africans under five models (Table [3](#T3){ref-type="table"}). Stratification analyses by SOC and genotyping method suggested that population-based studies or studies using MassARRAY method were easy to find the associations between *IL-10* rs1800896 polymorphism and risk of PCa. However, when stratified by HWE, there is no significant association in the HWE-positive groups or HWE-negative groups. Obviously, these studies deviating from HWE have effects on the overall results.

###### Meta-analysis for the effect of rs1800896 on the risk of prostate cancer

  Genetic model              Statistics            Heterogeneity   Publication bias                  
  -------------------------- --------------------- --------------- ------------------ ------ ------- -------
  Allele (G vs. A)           0.92(0.83,1.01)       0.089           \<0.001            66.7   0.857   0.590
  Dominant (GG+GA vs. AA)    0.92(0.79,1.08)       0.319           \<0.001            67.2   0.787   0.742
  Recessive (GG vs. GA+AA)   0.85(0.72,1.00)       0.052           \<0.001            62.6   0.928   0.418
  Homozygous (GG vs. AA)     **0.81(0.66,0.99)**   0.044           \<0.001            63.7   0.719   0.399
  Heterozygous (GA vs. AA)   1.02(0.85,1.23)       0.814           \<0.001            72.0   0.787   0.938

\*Bold values are statistically significant (*P* \< 0.05).

###### Summary of the subgroup analyses in this meta-analysis

  -------------------------------------------------------------------------------------------------------------------
  Comparison     Category    Category    Studies           OR (95% CI)            *P*-value   *P* for heterogeneity
  -------------- ----------- ----------- ----------------- ---------------------- ----------- -----------------------
  G vs. A        Ethnicity   Caucasian   11                **0.85(0.76,0.96)**    0.007       0.002

                             Mixed       1                 1.05(0.95,1.17)        0.312       N/A

                             African     2                 0.97(0.79,1.20)        0.786       0.773

                             Asian       2                 **1.44(1.06,1.97)**    0.020       0.886

                 SOC         PB          10                **0.85(0.75,0.96)**    0.008       \<0.001

                             HB          6                 1.10(0.97,1.24)        0.125       \<0.001

                 HWE         Positive    11                0.90(0.80,1.02)        0.097       \<0.001

                             Negative    5                 0.96(0.79,1.16)        0.654       0.128

                 Method      PCR         4                 0.91(0.70,1.17)        0.452       0.117

                             MassARRAY   3                 **0.89(0.81,0.97)**    0.006       0.625

                             Taqman      8                 0.90(0.77,1.07)        0.230       \<0.001

                             N/A         1                 1.47(0.97,2.23)        0.066       N/A

  GG+GA vs. AA   Ethnicity   Caucasian   11                **0.81(0.69,0.95)**    0.009       0.014

                             Mixed       1                 1.05(0.90,1.24)        0.525       N/A

                             African     2                 1.16(0.79,1.72)        0.445       0.643

                             Asian       2                 **1.96(1.02,3.78)**    0.043       0.102

                 SOC         PB          10                **0.83(0.71,0.97)**    0.021       0.004

                             HB          6                 1.23(0.86,1.78)        0.261       0.028

                 HWE         Positive    11                0.89(0.75,1.05)        0.163       0.001

                             Negative    5                 1.04(0.64,1.68)        0.870       0.002

                 Method      PCR         4                 0.79(0.46,1.37)        0.404       0.009

                             MassARRAY   3                 **0.83(0.72,0.96)**    0.012       0.333

                             Taqman      8                 0.94(0.77,1.14)        0.527       0.027

                             N/A         1                 **2.82(1.51,5.24)**    0.001       N/A

  GG vs.GA+ AA   Ethnicity   Caucasian   11                0.81(0.65,1.00)        0.054       \<0.001

                             Mixed       1                 1.09(0.92,1.30)        0.309       N/A

                             African     2                 0.85(0.62,1.16)        0.303       0.638

                             Asian       2                 0.85(0.45,1.63)        0.628       0.488

                 SOC         PB\         10\               **0.78(0.64,0.95)**\   0.012\      0.001\
                             HB          6                 1.06(0.77,1.46)        0.735       \<0.001

  HWE            Positive    11          0.87(0.73,1.04)   0.129                  0.003       

                 Negative    5           0.82(0.49,1.39)   0.471                  0.026       

  Method         PCR         4           1.01(0.43,2.39)   0.982                  0.010       

                 MassARRAY   3           0.87(0.76,1.01)   0.070                  0.589       

                 Taqman      8           0.84(0.65,1.09)   0.189                  0.001       

                 N/A         1           0.76(0.37,1.56)   0.462                  N/A         

  GG vs. AA      Ethnicity   Caucasian   11                **0.71(0.56,0.90)**    0.005       0.001

                             Mixed       1                 1.11(0.91,1.36)        0.305       N/A

                             African     2                 1.09(0.68,1.75)        0.731       0.985

                             Asian       2                 1.58(0.70,3.54)        0.233       0.919

                 SOC         PB          10                **0.69(0.54,0.88)**    0.002       \<0.001

                             HB          6                 1.26(0.97,1.64)        0.078       0.969

                 HWE         Positive    11                0.81(0.64,1.03)        0.085       \<0.001

                             Negative    5                 0.81(0.52,1.25)        0.336       0.164

                 Method      PCR         4                 **0.58(0.39,0.86)**    0.007       0.417

                             MassARRAY   3                 **0.79(0.66,0.94)**    0.008       0.676

                             Taqman      8                 0.84(0.60,1.17)        0.296       \<0.001

                             N/A         1                 1.58(0.70,3.54)        0.272       N/A

  GA vs. AA      Ethnicity   Caucasian   11                **0.90(0.72,1.11)**    0.328       \<0.001

                             Mixed       1                 1.03(0.87,1.22)        0.761       N/A

                             African     2                 1.25(0.83,1.88)        0.280       0.448

                             Asian       2                 2.27(0.89,5.82)        0.087       0.030

                 SOC         PB          10                **0.94(0.77,1.14)**    0.508       \<0.001

                             HB          6                 1.26(0.79,1.99)        0.329       0.004

                 HWE         Positive    11                0.92(0.79,1.07)        0.265       0.021

                             Negative    5                 1.35(0.80,2.28)        0.257       0.002

                 Method      PCR         4                 0.81(0.44,1.51)        0.513       0.003

                             Taqman      3                 1.00(0.64,1.58)        0.989       \<0.001

                             MassARRAY   8                 0.99(0.87,1.13)        0.907       0.350

                             N/A         1                 **3.77(1.90,7.47)**    \<0.001     N/A
  -------------------------------------------------------------------------------------------------------------------

SOC, source of controls; PB, population-based controls; HB, hospital-based controls; HWE: hardy-weinberg equilibrium.

![Forest plot shows odds ratio for the associations between *IL-10* rs1800896 polymorphism and PCa risk (GG vs. AA)](oncotarget-08-66204-g002){#F2}

![Stratification analyses of ethnicity between *IL-10* rs1800896 polymorphism and PCa risk (G vs. A)](oncotarget-08-66204-g003){#F3}

Heterogeneity and publication bias {#s2_3}
----------------------------------

High between-study heterogeneity was observed under five models. Meta-regression suggested that ethnicity (*P* = 0.163), HWE (*P* = 0.621) and genotyping method (*P* = 0.514) had no significant impact on the heterogeneity in ORs with *IL-10* rs180086 polymorphism except for SOC (*P* = 0.043). Consequently, SOC may be the main source of high heterogeneity. We assessed the sensitivity by omitting each study in turn to assess the effect of individual study on the overall estimated risk. The pooled ORs did not show a significant difference by removing any individual study, supporting that this meta-analysis was stable and trustworthy (GA vs. AA, Figure [4](#F4){ref-type="fig"}). Both Egger's and Begg's tests (GG vs. GA+AA, Figure [5](#F5){ref-type="fig"}) were used to evaluate the publication bias of this meta-analysis. No evidence of publication bias was found in this meta-analysis (Table [2](#T2){ref-type="table"}).

![Sensitivity analysis for the association between *IL-10* gene rs1800896 polymorphism and PCa risk (GA vs. AA)](oncotarget-08-66204-g004){#F4}

![Begg's tests between *IL-10* rs1800896 polymorphism and PCa risk (GG vs. GA+AA)](oncotarget-08-66204-g005){#F5}

DISCUSSION {#s3}
==========

The role of *IL-10* in tumor pathogenesis and development is a double-edged sword. Many studies have revealed the significant association between *IL-10* levels and poor prognosis. Moreover, *IL-10* is also thought to promote tumor immune escape by diminishing anti-tumor immune response in the tumor microenvironment \[[@R28]\]. Richter et al. found *IL-10* showed the anti-tumor effect on the suppression of angiogenesis and metastasis \[[@R9]\]. Notably, rs1800896 polymorphism in the *IL-10* gene promoter could affect *IL-10* production \[[@R29]\]. Recently, the association between the *IL-10* rs180086 polymorphism and various cancers has been reported widely, including esophageal cancer \[[@R30]\], oral cancer \[[@R31]\], gastric cancer \[[@R32]\] and colorectal cancer \[[@R33]\]. Of course, PCa is also among these cancers that could not be ignored. In 2002, McCarron et al. found that *IL-10* rs1800896 polymorphism could decrease the risk of PCa in the United Kingdom \[[@R19]\]. The significant association was confirmed in the subsequent studies among Caucasians \[[@R16], [@R22]\]. However, the remaining studies failed to uncover the association between the *IL-10* rs1800896 polymorphism and PCa risk in different races \[[@R5], [@R13]-[@R15], [@R17], [@R18], [@R20], [@R21], [@R23]-[@R25], [@R27]\].

To address this controversy, Shao et al. reviewed 10 studies involving 3,451 cases and 4,440 controls and performed a comprehensive meta-analysis in 2011 \[[@R34]\]. They found that there was no significant association between the *IL-10* rs1800896 polymorphism and the risk of PCa in the overall population \[[@R34]\]. In the subgroup analysis, negative results were also found among Caucasians and Asians \[[@R34]\]. In another meta-analysis involving 4846 cases and 5244 controls from 12 studies, Zou et al. \[[@R35]\] got the same findings as the meta-analysis conducted by Shao et al. \[[@R34]\]. In 2017, Ruan et al. \[[@R36]\] found that *IL-10* rs1800896 polymorphism was not associated with the risk of PCa in overall populations. However, they found rs1800896 polymorphism might increase the risk of PCa among Asians in the stratification analysis of ethnicity \[[@R36]\]. In this study, we re-evaluated the role of *IL-10* rs1800896 polymorphism in the risk of PCa by meta-analysis involving 12,811 subjects. Our data found that *IL-10* rs1800896 polymorphism was associated with the decreased risk of PCa. In addition, we think previous meta-analyses \[[@R34]--[@R36]\] had several limitations. First, Shao et al. \[[@R34]\] did not conduct a comprehensive research and omitted an article \[[@R5]\]. Second, Zou et al. \[[@R35]\] did not analyze the source of heterogeneity and conduct sensitive analysis to evaluate whether individual study could influence the overall result qualitatively. Third, Ruan et al. \[[@R36]\] did not include three studies \[[@R22], [@R25], [@R37]\] which actually conformed to the inclusion criteria. In addition, Ruan et al. extracted wrong genotype number of rs1800896 polymorphism from the study conducted by Wang et al. \[[@R16]\]. Consequently, the reliability of their results \[[@R34]--[@R36]\] should be interpreted with caution. We believe our meta-analysis has some strength over previous meta-analyses for the following reasons. One, we identified 16 studies including 6,301 cases and 6,510 controls with regard to rs1800896 polymorphism and the sample size of this meta-analysis was large enough. Two, sensitivity analysis indicated that our data about rs1800896 polymorphism were trustworthy and robust.

Recently, a study found *IL-10* can completely prevent antigen-specific T cell proliferation by inhibition of the antigen-presenting capacity of monocytes through downregulation of class II major histocompatibility complex (MHC) antigens on monocytes \[[@R38]\]. The finding suggested a mechanism for tumor cells escaping from immune surveillance. In addition, AA homozygotes of rs1800896 polymorphism in the *IL-10* gene could reduce the production of *IL-10* \[[@R39]\]. Based on these observations, we guessed that less *IL-10* was beneficial for immunological monitoring, reducing the possibility of tumor cell survival. It may partly explain the reason why *IL-10* gene rs1800896 polymorphism was associated with the decreased risk of PCa.

The stratified analyses further confirmed this significant association in population-based studies and studies using the genotyping method of MassARRAY. In addition, stratification analysis by ethnicity indicated that the G allele of rs1800896 could decrease the risk of PCa among Caucasians (11 studies involving 4,438 cases and 3,600 controls) and increase the risk of PCa among Asians (2 studies containing 360 cases and 358 controls), indicating different racial inheritance of Caucasians and Asians. This discrepancy may partly attribute to ethnicity-specific effect and sample sizes. For Caucasians, the minor allele G frequency was 0.467 in this meta-analysis, which was much higher than that of Asians (0.164). We hypothesized that genetic heterogeneity, clinical heterogeneity, different genotyping methods and random errors may also be the potential reasons for different findings between Asians and Caucasians. In addition, sample sizes in the subgroup of Asians were relatively small, thus the findings of Asians may be underpowered. Consequently, the results of Asian groups need be interpreted with caution. Further studies with larger sample sizes is necessary to confirm these hypotheses.

Multiple meta-analyses were conducted to investigate the association between *IL-10* rs1800896 polymorphism and cancer risk \[[@R40]-[@R42]\]. The meta-analysis conducted by Dai et al. found that *IL-10* rs1800896 polymorphism had no association with breast cancer risk in the overall population \[[@R41]\]. However, G allele of rs1800896 was demonstrated to significantly increase susceptibility to gastric cancer and digestive cancer \[[@R40], [@R42]\]. In this meta-analysis, we obtained an association between *IL-10* rs1800896 polymorphism and the decreased risk of PCa. In summary, the above findings may suggest that *IL-10* rs1800896 polymorphism has disease-dependent functionality, which may explain the inherent heterogeneity of tumor progression in different types of cancer.

Several potential limitations should be addressed in this meta-analysis. First, no further stratification analyses of other potential factors, such as age and familiar history due to lack of original data. Second, our results were based on unadjusted estimates for confounding factors, which might have affected the final conclusions. Third, the sample sizes of some individual studies were very small, which could deviate from the true results. Fourth, the results should be interpreted with caution due to high heterogeneity. Fifth, some bias may be unavoidable because only articles published in English and Chinese were identified in this study. Finally, the sample sizes of Asian groups were limited.

In conclusion, this meta-analysis indicates that *IL-10* gene rs1800896 polymorphism is associated with the decreased risk of PCa. *IL-10* gene may have an ethnicity-specific effect and disease-dependent functionality. Larger studies with more diverse ethnic populations are needed to confirm these results of this meta-analysis.

MATERIALS AND METHODS {#s4}
=====================

Search strategy and selection criteria {#s4_1}
--------------------------------------

PubMed, EMBASE, Google and CNKI databases were searched for all relevant articles up to April 1, 2017. The following search terms were used: ("prostate cancer" OR "prostatic neoplasm" OR "prostate carcinoma" OR "prostate neoplasms") AND ("polymorphism" OR "polymorphisms" OR "variant" OR "SNP" OR "SNPs" OR "rs1800896") AND ("Interleukin 10" OR "*IL-10*" OR "IL10" OR "Cytokine Synthesis Inhibitory Factor"). References in cited studies and review articles were also checked for other relevant articles. We included the latest study when one study overlapped with another one. PCa was diagnosed according to classification criteria.

Studies were included if they: (1) discussed the association between the *IL-10* rs1800896 variant and PCa; (2) provided sufficient data for calculating the pooled odds ratio (ORs) with 95% confidence interval (CI); (3) were case-control studies. Exclusion criteria were: (1) studies containing overlapping data; (2) case reports or reviews; (3) articles investigating other SNPs of *IL-10* gene.

Data extraction and quality assessment {#s4_2}
--------------------------------------

Two investigators extracted data from the original studies independently. From each study, the following information was extracted: name of the first author, publication year, country of origin, ethnicity, genotypes of cases and controls, and genotyping method. Authors were contacted to provide supplemental data if data were not available in the relevant articles.

The Newcastle-Ottawa Scales (NOS) were used to assess the quality of the selected studies \[[@R43]\]. Total NOS scores ranged from 0 (worst) to 9 (best). Only the studies with more than 5 stars based on the NOS scale were included in this meta-analysis. The discrepancies were resolved by consensus.

Evaluations of statistical associations {#s4_3}
---------------------------------------

Pearson's χ2 test was used to evaluate whether gene frequencies in the controls conformed to HWE. Pooled ORs with corresponding 95% CIs were calculated to evaluate the strength of the relationship between *IL-10* rs1800896 polymorphism and the risk of PCa. Stratification analyses were carried out by ethnicity, SOC, HWE and genotyping method. Heterogeneity between studies was detected by Cochran's Q-statistics. Generally, we considered the presence of significant heterogeneity at the 10% level of significance and values of I^2^ exceeding 50% as an indicator of significant heterogeneity. When no heterogeneity was found with *P* \> 0.10 or I^2^ \< 50%, a fixed-effect model was used. Otherwise, a random-effects model was applied \[[@R44]\]. To detect potential between-study heterogeneity, meta-regression was performed using the following covariates: ethnicity, SOC, HWE and genotyping methods. Sensitivity analysis was conducted to determine the effect of each study on the pooled ORs by omitting each study in turn. Publication bias was evaluated by visual inspection of symmetry of Begg's funnel plot and assessment of Egger's test \[[@R45]\]; *P* \< 0.05 was regarded as representative of statistical significance. All statistical analyses were performed using the Stata 11.0 software (StataCorp, College Station, TX, USA).
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